drugset / Trial / NCT05852431
To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia
RandomizedParallel-groupQuadruple-blindTreatment
Summary
To determine the effect of Pegozafermin on fasting serum triglyceride levels in subjects with Severe Hypertriglyceridemia (TG ≥500 to ≤2000 mg/dL) after 26 weeks of treatment.
Timeline
- Start
- 2023-06-15
- Primary completion
- 2025-07-07
- Completion
- 2026-04-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pegozafermin | Protein / enzyme biologic | 20 mg | Subcutaneous |
| Subject | Pegozafermin | Protein / enzyme biologic | 30 mg | Subcutaneous |
Indications
No indication recorded.